- Reviews (0)
|Applications||FACS IHC IP|
|Antigen/Gene or Protein Targets||CD19|
|Synonyms||CD19 Molecule; B-Lymphocyte Surface Antigen B4; T-Cell Surface Antigen Leu-12; Differentiation Antigen CD19; CD19 Antigen; CVID3; B4|
|Relevance||CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. It is a single chain glycoprotein, present on the surface of normal and neoplastic B-cells. CD19 is expressed at an early stage by projenitor B-cells in bone marrow and during all stages of B-cell maturation. This antigen is lost upon terminal differentiation to plasma cells. CD19 is important for detecting both normal and neoplastic B-cells. CD19 is present on neoplasms arising from early B-cells (e.g. acute leukaemia of pre-B-cells) and more differentiated B-cell neoplasms (e.g. chronic Lymphocytic leukaemia and non-Hodgkin's lymphoma). Leukaemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. The CD19 cytoplasmic domain binds tyrosine kinases and PI-3 kinase.|
|Immunogen||Human EB-4 Burkitt's lymphoma cell line|
|Recommended Growing Conditions||RPMI 1640 + 10% FCS|
|Notes||FACS dilution: 1/50 to 1/200|
|Research Area||Cancer, Cell Signaling & Signal Transduction, Immunology, Stem Cell Biology|
References: 5 entries
Bortolotti et al. 2016. Toxins (Basel). 8(6):. PMID: 27338475.
Flavell et al. 2006. Br J Haematol. 134(2):157-70. PMID: 16771848.
Behr et al. 1995. J Exp Med. 182(5):1191-9. PMID: 7595190.
Schlossman SF. et al. 1995. Leucocyte Typing V. Oxford University Press
Callard et al. 1992. J Immunol. 148(10):2983-7. PMID: 1374445.
Add a reference
Have you used this reagent? Share your experience by submitting a review and help your fellow scientists.Review this reagent